First Alzheimer’s drug from Eisai/UCL alliance to enter clinical trials
The first drug candidate from Eisai and University College London (UCL)’s drug discovery collaboration is to enter Phase I clinical trials for Alzheimer’s disease (AD) early next year.
Read More
